AllCells®, a subsidiary of Discovery Life Sciences™, has expanded its apheresis network by adding two new centers in Houston, Texas, and Huntsville, Alabama. These centers complement AllCells' existing presence in two major U.S. biotechnology hubs, namely the San Francisco Bay and Boston Metropolitan areas, which further solidifies its position as a market leader and strengthens its ability to meet the growing global demand for CGT products and services. AllCells is renowned worldwide for its high-quality services, with a 99% deliverability rate and strict adherence to quality standards. With over 3,700 CGT-focused clinical trials taking place globally, the company has invested heavily in expanding its collection sites and increasing its apheresis capacity to meet phase-appropriate requirements.
AllCells has also boosted its donor digital marketing, specialized recruiting, and event-hosting efforts, as well as increasing its experienced project management team to support new and ongoing GMP projects. AllCells offers tens of thousands of well-characterized, highly engaged, and recallable donors, along with in-house access to comprehensive analytical characterization, including cell biology, genomic, and proteomic capabilities. According to Danny Zheng, the President of AllCells, this expansion marks a significant milestone for the company in its mission to become the most trusted global supplier of CGT solutions, offering customers a highly characterized supply chain through a single robust and scaled resource as they pursue groundbreaking breakthroughs in the field of CGT.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!